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ABSTRACT
Stress hormones, adrenaline and noradrenaline, have been shown to be critical for heart
development. Mice lacking dopamine β-hydroxylase (Dbh), an enzyme responsible for synthesis
of these adrenergic hormones, die during mid-gestation due to cardiac failure. Prior research
showed that adrenergic cells are found within the electrical conduction system of the heart, and
adrenergic deficiency leads to slowed cardiac conduction during embryogenesis. Microarray
analysis of wild-type (Dbh+/+) and knockout (Dbh-/-) mouse hearts revealed significant
differences in expression of retinoic acid (RA) signaling genes. RA signaling has also been
shown to be critical for heart development. These data suggest that heart failure due to
adrenergic deficiency may be dependent upon RA signaling. This led to the hypothesis that
adrenergic hormones promote the development of the electrical conduction system through
modulation of RA signaling. To test this, embryonic mouse hearts were cultured with LE 135, a
RA receptor blocker. Heart rate, arrhythmic index (AI) and conduction time were measured.
Under these conditions there was a marked increase in arrhythmias. Hearts treated with LE 135
showed a mean AI of 0.232±0.057 after 24 hours of treatment while when untreated had an AI of
0.083±0.028 (p<0.05;n=15). In contrast, there was no significant change in heart rate or
conduction speed after 24 hours with or without the retinoic acid receptor blocker. To determine
if adrenergic stimulus influences retinoic acid response, an established RA-sensitive reporter cell
line was employed. These F9-RARE-LacZ cells were treated with forskolin (cAMP regulator)
and isoproterenol (β-agonist) to measure changes in RA signaling. Evaluation of RA signaling
showed an increase in retinoic acid responsiveness when treated with an adrenergic signaling
agonist. These results suggest that proper retinoic acid signaling is essential for maintaining
iii

cardiac rhythmicity during embryonic development and adrenergic stimulation can influence this
response.
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CHAPTER ONE: INTRODUCTION
According to the Center for Disease and Control, heart disease is the leading cause of
death in the United States and every minute an individual dies from this terrible disease (“CDC
Features – February is American Heart Month,” 2011 ). Heart disease can have several causes
from congenital heart defects to obesity. Key cardiac disorders that can cause a heart attack and
ultimately lead to heart failure are conduction disruptions and arrhythmias. The cardiac
conduction system is responsible for synchronized, rhythmic contractions. The heart has a
natural pacemaker called the sinoatrial (SA) node which is located in the right atrium. It is
responsible for the electrical stimulus which causes the heart to beat. There can be disturbances
from the SA node which lead to abnormal conduction (“Heart block,” 2011). Problems with
conduction can lead to increases in arrhythmias. Arrhythmias are characterized by a disorder that
causes irregular rhythmic beating of the heart (“Arrhythmias,” 2009). These arrhythmias can
indicate serious problems with the electrical conduction system of the heart. Understanding the
molecular mechanisms that cause problems in the electrical conduction system of the developing
heart can give a better understanding of heart development and ultimately aid in combating heart
disease and failure. An important potential mechanism is the role of adrenergic hormones during
cardiac development and their possible connection to retinoic acid signaling to maintain proper
cardiac conduction and rhythmicity during embryogenesis.
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Overview of Retinoic Acid

Figure 1: Overview of retinoic acid synthesis and signaling

Retinoic acid is a derivative of vitamin A (retinol). The function of vitamin A in tissues is
usually carried out by its acidic form, retinoic acid, and at the cellular level it functions as a
hormone. The synthesis of retinoic acid involves two main enzymatic steps. First, a member
from the alcohol dehydrogenase (ADH) family oxidizes retinol into retinaldehyde (retinal). Also,
through a different pathway β-carotene 15,15’-monooxygenase (BCMO) can convert beta
carotene into retinal (Boulanger et al., 2003). Once retinal is produced, class I aldehyde
dehydrogenase (ALDH) family members convert retinaldehyde into retinoic acid (Niederreither
et al., 2001). Retinoic acid is then utilized as a signaling molecule, acting through nuclear
receptors. Retinoic acid receptor (RAR) and the retinoid X receptor (RXR) function as
heterodimers, binding to retinoic acid response elements (RARE) on the target DNA (Figure 1).
Three genetic isotypes are found of each receptor, in the form of either RARα, β, or γ and RXRα,
β, or γ. Each receptor gives a unique pattern of expression during embryogenesis. Once retinoic
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acid binds to each of these receptors, transcription of target genes can be initiated (Gruber et al.,
1996).
Retinoic acid plays important roles in the body and has been shown to be essential for
vision, organ, and immune function throughout the life of an adult. It plays its main function in
areas where vitamin A is known to have a significant role such as the kidney, liver, and plasma.
Retinoic acid is also found in smaller amounts in areas of the body like the eye and epithelial
tissues (McLaren & Frigg, 2001). Retinoic acid is also essential as an anti-inflammatory
response and can have a therapeutic effect on autoimmune diseases (Mucida et al., 2007).
Although not much is known as to the exact role and amount of retinoic acid in the adult
organism, it is essential in areas where vitamin A is necessary.
Not only is retinoic acid important in maintenance of an adult individual, it has been
shown to have a significant impact on embryonic development. In general, retinoic acid during
embryogenesis is essential for epithelial differentiation, organ maturity, embryonic circulation,
central nervous system development, lymphoid organ functions, as well as immune and vision
development (Ross, McCaffery, Drager, & De Luca, 2000). During embryogenesis, both an
over-abundance and lack of retinoic acid can have deleterious effects on development. When
there is an excess of retinoic acid, studies have shown that the fetus becomes malformed which
can change epithelial characteristics that can eventually lead to death. When there are insufficient
amounts of retinoic acid during embryogenesis, growth of the embryo begins to fail and
vascularization begins to decline which too can lead to death of the embryo (Ross et al., 2000).
Thus, maintenance of retinoic acid homeostasis is a vital component during fetal development.
Changes in retinoic acid can have deleterious effects on embryogenesis, specifically with
regards to cardiac development. Most notably, retinoic acid has been shown to be essential in
3

the development of cardiac structures, but too much retinoic acid can lead to serious cardiac
problems as well (Dyson et al., 1995). When embryos were treated with excess retinoic acid,
malformations of cardiac structures such as aortic arch abnormalities and ventricular septal
defects were noted. The contraction rates and α-actinin expression decreased significantly. This
could indicate that retinoic acid effects myofibril formation as well as the overall cardiac
structure formation of the developing heart (Dickman & Smith, 1996).
Many studies have been conducted that block retinoic acid signaling and have also shown
to have negative consequences on the embryonic heart. In one study, mice that were RXRα -/and thus unable to propagate retinoic acid signaling, developed cardiac septal defects, ventricular
chamber hypoplasia, and eventually died in utero during midgestation (Dyson et al., 1995).
Serious defects of the conduction system of the developing heart were noted in RXRα -/- mice.
Compared to wild-type mice, the RXRα -/- mice developed atrioventricular block, a slower heart
rate, and the ventricular contraction rate decreased (Dyson et al., 1995). Also, when retinoic acid
signaling decreased by blocking the same previous receptor, aortic sac abnormities, ventricular
muscle, and atrioventricular cushion defects also resulted (Gruber et al., 1996). Thus, lack of
retinoic acid leads to critical cardiac defects.
Adrenergic Hormones Essential for Cardiac Development
The stress hormones, epinephrine (adrenaline) and norepinephrine (noradrenaline) are
mainly produced by the sympathetic nervous system and the adrenal medulla. These
catecholamines have been shown to have an essential role in the body. They are often referred to
as “flight or fight” hormones because they lead to the activation of the sympathetic nervous
system and have their various effects on several organ systems such as the lungs, liver, and
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skeletal muscle through different subsets of adrenergic receptors. Metabolic effects include
glucose release, glycogenolysis, and lipolysis. Adrenergic hormones act through adrenergic
receptors. There are two types: alpha (α) and beta (β) with specific subtypes (α1, α2, β1, β2, β3)
depending on the effector organ. For example, β1 adrenergic receptors primarily increase cardiac
pumping, heart rate, and contractility, while other adrenergic receptors exist for other functions
(Fox, 2006).
Adrenergic hormones are produced in the adrenal medulla or through the nervous system
stimulation acting as a neurotransmitter (Fox, 2006). The hormones bind to their G protein
coupled receptor which triggers a signaling cascade involving cyclic adenosine monophosphate
(cAMP) which prompts the activation of a protein kinase. This has the effect of activating or
inactivating enzymes and opening ions channels, having the fundamental effect of regulating
physiological responses (Rochais et al., 2006).

Figure 2: Pathway of catecholamine biosynthesis. Key enzyme dopamine β-hydroxylase (red)
essential for norepinephrine synthesis
The enzyme dopamine β-hydroxylase (Dbh) is essential for the production of adrenergic
hormones. It has the ability to convert dopamine into norepinepherine (NE), a key step in
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catecholamine synthesis (Figure 2). Norepinephrine can further be converted to epinephrine
(EPI) using the enzyme phenylethanolamine n-methyltransferase (Pnmt). Mice lacking the Pnmt
gene are unable to produce epinephrine; however, they are viable and appear to have no
development defects. Once the Dbh gene is knocked out, mice can no longer synthesize
norepinephrine and most of those embryos die before the sympathetic nervous system even
develops. Most of the mice lacking Dbh died after embryonic day 10.5 (Thomas, Matsumoto, &
Palmiter, 1995) Two key points can be noted, norepinephrine is essential in embryonic survival
and there is also a critical window in which adrenergic hormones are needed for cardiac
development (Ebert & Taylor, 2006). Consequently, catecholamines are a fundamental
component of cardiac embryogenesis.
Previous research has shown that intrinsic cardiac adrenergic (ICA) cells capable of
producing adrenergic hormones are found in and around the electrical conduction system of the
heart. It has been observed that catecholamines are present during early embryonic development
and may be needed for proper rhythmic contractions since the cells are shown to be localized in
areas associated with cardiac pacemaking (Ebert & Thompson, 2001). Ongoing research from
the laboratory of Dr. Steven Ebert showed that mice which were adrenergic deficient (Dbh -/-)
had slower atrioventricular conduction compared to wild-type (Dbh+/+) embryonic mouse hearts.
Also, the adrenergic deficient hearts have increased atrioventricular blockage around E10.5 (Dr.
David Taylor, Dr. Steven Ebert, unpublished).
Preliminary microarray data from the laboratory of Dr. Steven Ebert lab was performed
to analyze gene expression changes of embryonic mice which were lacking dopamine βhydroxylase (Dbh -/-). This method looked at all the genes of the Dbh -/- mouse genome and were
compared to Dbh +/+ mice. When comparing the knockout mouse with the wild-type, 23 genes
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showed significant changes in expression that was 2-fold or greater. Further analysis also showed
that several of the genes that had altered gene expression were directly related to retinoic acid
synthesis such as beta-carotene 15,15'-monooxygenase (BCMO), a key enzyme involved in one
of the first steps of retinoic acid biosynthesis. Other genes related to retinoic acid also showed
changes in the microarray study such as CRABP-1, CRABP-2, RALDH1 and RBP-1 (Kingsley
Osuala, Dr. Steven Ebert, unpublished). These findings imply a possible correlation between
mice that are unable to produce norepinephrine and retinoic acid regulation, and suggest that the
lethality of Dbh -/- mice might be a result of alteration of retinoic acid synthesis.
A potential mechanistic connection between retinoic acid signaling and adrenergic
hormones may have to do with cyclic adenosine monophosphate (cAMP). As previously
mentioned, cAMP is essential in the signaling cascade of adrenergic stimulation. The cAMP
response element binding protein can regulate the gene expression of BCMO1. The human
BCMO1 promoter has been found to include a cAMP response element. cAMP is able to active
the Cre binding protein which can help drive transcription of the BCMO1 gene, promoting
retinoic acid production (Lietz, Lange, & Rimbach, 2010). Given that both adrenergic and
retinoic acid signaling involve cAMP, regulation of cAMP could be a possible link between their
pathways, although other viable connections may still exist.
Rational
Considering previous literature and the microarray data, a correlation between retinoic
acid signaling and cardiac conduction is formulated. Embryonic mice lacking the enzyme Dbh
began dying of heart failure around embryonic day 10.5 and additionally, preliminary data shows
that Dbh -/- have conduction defects. Microarray data has already shown that Dbh -/- have
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abnormal retinoic acid signaling. Therefore, it may be inferred that the cardiac conduction
problems found in adrenergic deficient mice may be the result of altered retinoic acid signaling.
Consequently, the goal of this study was to determine if changes in retinoic acid signaling effect
cardiac electric conduction properties by measuring heart rate, conduction and rhythmicity
during embryogenesis, and to test whether there is a mechanistic connection between adrenergic
hormones and retinoic acid signaling.
Aims
The first aim was to determine if blockage of retinoic acid signaling would lead to
changes in cardiac rate, rhythm, and electrical conduction properties in Dbh +/+ wild-type mice.
If blockage of retinoic acid signaling caused arrhythmias and conduction defects in the Dbh +/+
mice this would suggest retinoic acid is essential for maintaining proper cardiac conduction and
rhythmicity during embryonic development and may also suggest that the lethality seen in Dbh -/could be from alteration in retinoic acid signaling.
The second aim was to determine if there is a connection between adrenergic hormone
production and retinoic acid signaling. This was done using the F9-RARE-LacZ cell line which
has been constructed with the LacZ reporter system. Cells were cultured in different
concentrations of retinoic acid, forskolin (cAMP regulator), and isoproterenol (β-agonist), and
changes in retinoic acid response was measured. If changes occur with the addition of the
adrenergic mimics it will illustrate a mechanistic connection between retinoic acid signaling and
adrenergic hormones.
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CHAPTER TWO: MATERIALS AND METHODS
Overview of Methodology
The procedure was divided into two main parts. The first part of the experiment used the
Dbh +/+ mice and the retinoic acid receptor antagonist. The embryonic hearts were obtained at
embryonic (E) day 10.5. The specific antagonist that was used in the experiment was LE 135,
which competitively binds to retinoic acid receptors and will be used to mimic blockage of
retinoic acid signaling (Li, Hashimoto, Agadir, Kagechika, & Zhang, 1999). A maximum
number of hearts were isolated and the embryonic hearts were then allowed to culture for 24
hours in drug treatment. Before any drug was placed on the hearts, a video was taken for at least
90 seconds. After the hearts have cultured for 24 hours, another video was taken for at least 90
seconds.
Due to experimental timing and scheduling, data was analyzed using two methods:
photodiode technology and microelectrode array (MEA). First, the photodiode system was used
which utilizes diodes measuring the light changes on the video screen; a data read out with heart
rate and rhythmicity measurements was then obtained using this system. In the next set of
experiments, hearts were transported on MEA’s to the NanoScience Technology Center at the
University of Central Florida and a computer software was used to read the electrical impulses
produced. Once the data was obtained, heart rate, conduction measurements and overall
rhythmicity of the developing heart was analyzed using statistical analysis.
F9-RARE-LacZ cells were then employed for the second part of experimentations. These
cells were cultured with different drug concentrations and a fluorescent substrate was used to
measure changes in fluorescence in photons/mg/mL.
9

Animals
The strain of mice used were wild-type mice which were able to produce Dopamine βhydroxylase, Dbh +/+. The animal surgeries were all performed by trained individuals and all
procedures were in accordance with NIH guidelines and approved by the University of Central
Florida Animal Care and Use Committee.
The vaginal plug dates of the mice were checked and noted. Noon of the first day plug
day was assigned E0.5. 10 days later the mice were ready for surgery. E10.5 was used because it
corresponded to the date when the most of the Dbh -/- would die because of the lack of adrenergic
hormones (Thomas et al., 1995). As surgeries were performed and the embryos isolated, size of
the embryo was also noted. The specific embryos isolated were the same size, corresponding to
the 10.5 embryonic day.
Heart Cultures (Ex-Vivo)
Once the embryos were obtained they were isolated under aseptic conditions. They were
cultured in cardiac differentiation media which consisted of Dulbecco’s Modified Eagle’s Media
(DMEM) containing v/v of 15% charcoal stripped fetal bovine serum, 1 % PenStrep, 0.1% 2mercaptoethanol, 0.01 % non-essential amino acids, and 0.01 % glutamine (All products from
Invitrogen Inc., Carlsbad, CA).
Drug Treatment
For the first component, embryonic hearts were isolated. Once obtained they were placed
in the heart culture on petri dishes with MEAs, corresponding drug treatment also needed to be
placed in the culture. 10 µL of 100 nM of LE 135 (Tocris biosciences, Ellisville, MO) was used
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for the retinoic acid receptor antagonist treated hearts. The control hearts were given the same
volume but treated with 10 µL of dimethyl sulfoxide (DMSO, Sigma Aldrich, St. Louis, MO).
Video Recording
Once the culture was ready and the corresponding drugs were placed in each heart
culture, the plates were put into a custom glass chamber which was temperature regulated to
about 37 °C. The plate was placed on an Olympus CK2 inverted microscope which was
connected with a camera. This recording would play on a nearby computer screen. All hearts
were recorded for approximately 90 seconds on 10x magnification. They were recorded at 0
hours and after 24 hours of LE 135 or DMSO treatment. Any of the embryonic hearts which
were not beating at this point were discarded for no further use. After all the hearts were
recorded, they were placed in a 37 °C incubator for 24 hours supplied with 95% air and 5 %
CO2.
Photodiode Technology
From the computer screen, a photodiode system was connected. This consisted of two
diodes which were connected to an oscilloscope that reported heart rate and arrhythmia
measurements. One diode was placed on a portion of the screen that had no light change, this
would serve as the control. The other diode was placed on the screen where the embryonic heart
was located. The diodes could pick up on the changes in light on the screen as the heart would
beat. As it recorded, a readout of the heart rate and cycle length was obtained through software
acquisition (Ratcell Recorder, LabVIEW v4.0.1, National Instruments, Austin, TX). After all of
the hearts were recorded, a final readout with the calculated heart rate in beats per minute and
arrhythmia measurements could be obtained for analysis.
11

Microelectrode Array
For conduction measurements, MEA plates with the embryonic hearts were carefully
transported to the NanoScience Technology Center of the University of Central Florida. There a
similar readout was obtained but with conduction time measurements. At the center of the 8x8
MEA (#200/10iR-Ti, Multichannel Systems, Reutlingen, Germany) was a gelatin coating. The
hearts were placed at the center of the MEA, making sure that they touched the electrodes. The
Clampfit v10.0 software (Molecular Devices, Sunnyvale, CA) and MC_DataTool v2.6.0
(Multichannel Systems, Reutlingen, Germany) was used to analyze the electrode array data.
Atrioventricular conduction was measured as the time for impulse to travel from the SA node to
the apex of the heart (Figure 3). The cycle length was measured from one ventricular beat to the
other.

Figure 3: Isolated embryonic mouse hearts extracted at E10.5. Normal conduction flows from
SA node toward the apex of the heart
12

Obtaining Data and Analysis
Once the data was obtained from both the photodiode system and the MEA plates, it had
to be analyzed. Hearts rates were already obtained from recording before and after drug
treatment. The heart rate was obtained in beats per second and then converted to beats per
minute. Conduction velocity was obtained using the MEA analysis which takes into account
depolarization from one cycle event to the next. The major indication of rhythmicity was the
arrhythmic index (AI). This was calculated by obtaining the cycle length from all of the
recordings and putting the data into the program Prism (Graphpad Software, La Jolla, CA). Once
in the program, statistics were obtained, specifically, the median and standard deviation. The AI
could be calculated by dividing the median by the standard deviation (Fink et al., 2009). A
greater AI was indicative of a more arrhythmic heart.
F9-RARE-LacZ Reporter Cell Line
F9-RARE-LacZ reporter cell line was employed. The cells were donated by Dr. Michael
Wagner of Downstate Medical Center. The cells are transfected with the LacZ gene downstream
from the retinoic acid response element. Therefore, when retinoic acid signaling is stimulated,
LacZ is transcribed producing the protein product β-galactosidase (Wagner, Han, & Jessell,
1992). Fluorescein di-β-D-galactopyranoside (FDG, Sigma Aldrich, St. Louis, MO) is the
substrate whose fluorescence can be measured (Figure 4).
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Figure 4: Basic mechanism of F9-RARE-LacZ reporter assay

Cells were maintained in media containing 50% L-15 Leiboitz media (Sigma Aldrich, St.
Louis, MO) 50% DMEM, and 5% FBS v/v. The cells were grown to confluency in two 60 mm
cell culture dishes. They were trypsinized with 0.5 mL of 0.25% trypsin (Invitrogen Inc.,
Carlsbad, CA) for about five minutes to break up cells. Then, 4.5 mL of warm passage media
was added to the dish. The two 60 mm cell culture dishes were combined into one conical tube,
making sure all cells where mixed through the tube. They were then added to media to make the
desired volume needed for experimentation.
The cells were allowed to grow overnight to confluency on the 24 well plates. They were
then treated with varying concentration of drugs, (purchased from Sigma Aldrich, St. Louis,
MO) retinoic acid (all-trans retinoic acid, diluted in DMSO), forskolin (diluted in DMSO), or
isoproterenol ((−)-isoproterenol hydrochloride, diluted in 0.1 N HCl). The drugs were diluted in
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separate media to appropriate concentrations. Old media was removed from plates and media
with drugs was then placed into wells with cells.
The cells were allowed to culture in drug treated media for 24 hours. The media was
removed and the cells were lysed using 100 µL Glo Lysis Buffer (Promega Corporation,
Madison ,WI). A 96 well plate was needed to run assay. 70 µL of PBS was pipetted into each
well with 20 µL of supernatant of the lysed cells. Florescence was measured using Wallac
Envision 2104 Multilabel Reader (Perkin Elmer, Waltham, MA) which was programmed to read
fluorescein activity. Then 2 µL of 1 mM FDG was added and readings were taken every five
minutes for sixty minutes. Data was extrapolated from the change in FDG concentration based
on the formed linear curve. Data was normalized to include protein concentrations in mg/mL.
Fold change could then be calculated by dividing the average from the wells which had no drug
treatment.
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CHAPTER THREE: RESULTS
Heart Rate
To determine if the retinoic acid receptor antagonist LE 135 effects embryonic heart rate,
hearts were isolated into two treatment groups. 18 hearts served as controls, treated with 10 µL
of DMSO. The initial heart rate of the DMSO heart at 0 hours was 145.4 BPM with a standard
error of the mean (SEM) of 10.1 (145.4±10.10 BPM). After 24 hours of treatment the average
heart rate of the DMSO treated heart was 144.8±11.58 BPM. 15 hearts were treated with the
retinoic acid receptor blocker, LE 135. The average initial heart rate of the LE 135 treated hearts
was 138.8±10.65 BPM and after the 24 hours of treatment the heart rate was 131.9±62.52 BPM.
There was no significant change in heart rate of either group between their initial reading and 24
hours after drug treatment (Figure 5).
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Figure 5: Comparison of heart rates at 0 hours of treatment versus after 24 hours with or without
retinoic acid receptor antagonist (100 nM LE 135)
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Conduction
Conduction time and cycle length were measured to see the effects of the retinoic acid
receptor antagonist on heart conduction. A sample size of 4 hearts was available to obtain
conduction time and cycle length measurements. Atrioventricular conduction time and cycle
length was measured after 24 hours of treatment (Figure 6). The conduction time after 24 hours
of the DMSO (control) hearts was 65.82±10.510 ms while the LE 135 treated hearts had an
average conduction time of 78.74±9.359 ms. The cycle length of the DMSO treated heart after
24 hours of treatment was 0.6468±0.155 s while LE 135 treated heart had an average cycle
length of 0.7928±0.210 s. While both the conduction time and cycle length increased compared
to the control, DMSO treated hearts, the increase was not statically significant.
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Figure 6: Conduction time and cycle length measurements after 24 hours of treatment with or
without retinoic acid receptor antagonist (100 nM LE 135)
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Arrhythmias
To assess arrhythmic occurrences, arrhythmias were measured as a function of
arrhythmic index (AI) as previously mentioned in the methods sections and graphed comparing
initial and 24 hour readings (Figure 7). The higher the AI, the more significant the arrhythmias
associated with the heart. 18 hearts were used as control hearts treated with DMSO. The average
initial AI of the DMSO treated heart was 0.1224±0.252 and after 24 hours of treatment the AI
was 0.1195±0.025. 15 hearts were used to measure AI of the LE 135 treated. The initial AI of the
LE 135 treated hearts was 0.08317±0.028 and after 24 hours of treatment the AI increased to
0.2329±0.057. A ttest comparing the difference in AI of the LE 135 gave a p value of 0.0268,
indicating a statically significant increase after the addition of LE 135. When fold change was
examined, the DMSO treated hearts did not have a significant fold change while the LE 135
treated hearts have almost a 3 fold increase after 24 hours of drug treatment.
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Figure 7: Difference in AI at 0 hours of treatment versus 24 hours with or without retinoic acid
receptor antagonist (100 nM LE 135)
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Retinoic Acid Dose Response
To evaluate a mechanistic connection between retinoic acid and adrenergic hormones, a
reporter cell line was used. Retinoic acid dose response was measured using the F9-RARE-LacZ
cells. The cells were treated with varying concentrations of retinoic acid as previously described
in the methods sections. Different experiments were normalized using fold change compared to
cells treated with no drug (Figure 8). 14 wells with the F9-RARE-LacZ cells were treated with 1
nM RA and the average fold change was 2.187±0.160. 14 wells were treated with 10 nM RA and
the average fold change was 3.255±0.105. 15 wells were treated with 100 nM RA and the
average fold change was 4.404±0.467. This data was plotted and a linear line was obtained when
the 10 fold increments of RA were plotted against fold change with a R2 value of 0.9996.

Figure 8: Dose dependent relationship in F9-RARE-LacZ cells after treatment of retinoic acid

19

Different Concentrations of Forskolin and Isoproterenol
In a small initial experiment varying concentrations of forskolin (FK) and isoproterenol
(ISO) were used to see if any changes would occur in retinoic acid response using the F9-RARELacZ cells compared to the same cells with no drug (Figure 9). 0.1 µM FK had a mean fold
change of -0.7243±0.656 (n=4), 1 µM FK had a mean fold change of -0.5722±0.620 (n=9), and
10 µM FK had a fold change of 0.1674±0.841 (n=4). 10 nM ISO had a mean fold change of
0.01164±0.669 (n=4), 100 nM ISO had a mean fold change of 0.2111±0.996 (n=9), and 1 µM
ISO had an average fold change of -0.7175± 0.584 (n=4). Fold change in the range of -1 to +1 is
indicative of no fold and since all values were in this range, it was inferred that varying
concentrations of FK or ISO had no effect on retinoic acid concentration alone. Therefore, the
middle concentrations of each drug, 1µM FK and 100 nM ISO were used for further
experimentation.
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Figure 9: RA response with different concentrations of forskolin and isoproterenol alone on F9RARE-LacZ cells
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F9-RARE-LacZ Cells Treated with Forskolin
To determine the effects on RA response after the addition of a β-agonist, cells were
cultured with the cAMP regulator, forskolin in combination with retinoic to compare changes in
retinoic acid response to just retinoic acid alone. Fold change was then calculated and compared
to graphs with just retinoic acid (Figure 10). 1 nM RA in combination with 1 µM FK had an
average fold change of 2.911±0.313 (n=11). 10 nM RA in combination with 1 µM FK had an
average fold change of 3.755±0.270 (n=11). 100 nM RA in combination with 1 µM FK had an
average fold change of 5.812±0.336 (n=11). One way ANOVA shows overall means to be
statically significant (P<0.0001).
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Figure 10: Comparison of fold change in RA response after the addition of forskolin in
combination with retinoic acid
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F9-RARE-LacZ cells Treated with Isoproterenol
Cells were cultured with another β-agonist, isoproterenol in combination with retinoic
acid to compare changes in retinoic acid response to just retinoic acid alone. Fold change was
then calculated and compared to graphs with cells treated with just retinoic acid (Figure 11). 1
nM RA in combination with 100 nM ISO had an average fold change of 3.168±0.431 (n=12). 10
nM RA in combination with 100 nM ISO had an average fold change of 3.797±0.306 (n=11). 100
nM RA in combination with 100 nM ISO had an average fold change of 5.496±0.539 (n=11).
One way ANOVA shows overall means to be statically significant (P<0.0001).
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Figure 11: Comparison of fold change in RA response after the addition of isoproterenol in
combination with retinoic acid
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CHAPTER FOUR: DISCUSSION
This study examined the effects of blockade of retinoic acid signaling on embryonic
mouse hearts at day 10.5 to see if similar occurrences in electrical conduction were noted as seen
with Dbh -/-mouse hearts around the same period of time. The second part of the study examined
if there was an intrinsic relationship between retinoic acid signaling and adrenergic hormone
action.
First, electrical conduction properties were measured in hearts cultured for 24 hours with
the retinoic acid receptor blocker, LE 135. There was no significant change in heart rate between
the LE 135 treated hearts and the control group, treated with DMSO. Which means on average
the number of beats per minute produced by the LE 135 treated hearts and the DMSO treated did
not change.
Conduction time and cycle length were calculated using microelectrode arrays. After 24
hours of drug treatment the conduction time and cycle length were obtained. Conduction time
was measured from atrial depolarization to next spike intensity, the ventricular depolarization.
The cycle length was the time it took to go from one ventricular peak to the next. The results
show that there was an increased trend in conduction time and cycle length, but this trend was
not statically significant. There was a small sample size used for this portion of the experiment
but a larger sample size would be helpful to come to a more accurate conclusion.
Arrhythmia data was obtained as a function of arrhythmic index (AI). To make sure there
were no errors between the recordings and data, the videography was checked visually to see if
hearts were arrhythmic. When hearts were treated with DMSO for 24 hours there was no
significant change in AI. However, the hearts which were treated with the retinoic acid receptor
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blocker LE 135 had an almost three fold increase in AI. The results indicate that when retinoic
acid signaling is blocked there is an increase in arrhythmias in normal wild-type embryonic
mouse hearts. These results suggest that retinoic acid is essential in maintaining cardiac
rhythmicity of the developing heart.
To further evaluate if there is any mechanistic connection between retinoic acid signaling
and adrenergic hormone action, F9-RARE-LacZ cells were employed. When cells were treated
with increasing concentrations of RA in 10 fold increments, 1 nM RA, 10 nM RA, 100 nM RA a
linear line was obtained from the fold change averages with 10 fold increases in RA
concentration. These results indicate proper experimentation and a dose dependent relationship
because if there is a higher concentration of retinoic acid applied to the cells there is more
retinoic acid available to bind to its receptor. Therefore, more transcription of the LacZ gene
takes place which will encode for more β-galactosidase, giving a higher fluorescent reading after
the addition of the substrate FDG.
In the next experiment, it was shown that different concentrations of forskolin and
isoproterenol had no overall effect on transcription of LacZ on the F9-RARE-LacZ cells
compared to cells which had no drug treatment. This indicates that when cells are treated alone
with an adrenergic stimulus there was no additional stimulation of the LacZ gene, meaning it had
no effect on the amount of RA binding to the receptor on the cells.
However, additional experiments were done to measure the effects of beta adrenergic
signaling in combination with retinoic acid. The same concentrations of retinoic acid were used
(1, 10, 100 nM RA), but a constant concentration of forskolin (1 µM) and isoproterenol (100
nM) was used. These results indicate an increase in retinoic acid response after the addition of
one these two adrenergic agonist. It seems that forskolin and isoproterenol are sensitizing RA to
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bind to its receptor, increasing RA response because the curve too has a similar correlation but
with an increased fold change. Isoproterenol is mimicking adrenergic action which NE and EPI
would exhibit (Vaniotis et al., 2011). Forskolin in more downstream of the signaling, meaning it
bypasses the point where a direct adrenergic hormone would have to bind to the receptor to
initiate a signaling cascade, thus directly regulating cAMP in the process (Barman, Choisy,
Hancox, & James, 2011). Since both isoproterenol and forskolin effect adrenergic signaling, it
makes sense that their response was similar.
The overall results of the study suggest retinoic acid signaling is essential for proper
rhythmicity during embryonic development and may be dependent on adrenergic action. Since
Dbh -/- mice experienced conduction abnormalities during the same critical time of E10.5, and
this study finds that retinoic acid causes a significant increase in arrhythmias. The lethality seen
in the Dbh -/- could be the direct result of disruption of retinoic acid signaling. While adrenergic
dependence is suggested through the F9-RARE-LacZ reporter cell line study, further
experimentation should be done to fully evaluate this possibility.
For future research, electrical conduction properties of embryonic hearts treated with just
adrenergic hormones should be measured, and then after addition of retinoic acid to see if
rhythmic changes occur. Also, using the F9-RARE-LacZ cell line, further studies should be
conducted with different adrenergic stimulus. A constant retinoic acid concentration should also
be used with varying concentrations of adrenergic stimulus to see if any changes occur in
retinoic acid response. To test whether cAMP is involved in both signaling process, other cAMP
regulators like dibutyryl cAMP should be used to treat the cells. Since it is still unclear of the
exact connection between retinoic acid signaling and adrenergic hormone action, it is essential to
evaluate these and other parameters of research.
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